Drugs / MET233
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07022977 | Nov 2024 → Apr 2026 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06924320 | Mar 2025 → Sep 2026 expected | obesity disorder | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Met-233 | “Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234.” PMID 41747885 ↗ Feb 2026 |
| Route | Subcutaneous | “subcutaneous (SC) doses of MET233 co-administered with MET097” NCT06924320 ↗ |